<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Mater.</journal-id>
<journal-title>Frontiers in Materials</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Mater.</abbrev-journal-title>
<issn pub-type="epub">2296-8016</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1255955</article-id>
<article-id pub-id-type="doi">10.3389/fmats.2023.1255955</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Materials</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Synthesis of novel acylated and esterified ciprofloxacin derivatives as efficient anticancer and antimicrobial agents</article-title>
<alt-title alt-title-type="left-running-head">Alasadi and Al-Obaidi</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fmats.2023.1255955">10.3389/fmats.2023.1255955</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Alasadi</surname>
<given-names>Gheith M.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2425137/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Al-Obaidi</surname>
<given-names>Zaid</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2015332/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Pharmaceutical Chemistry</institution>, <institution>College of Pharmacy</institution>, <institution>Mustansiriyah University</institution>, <addr-line>Baghdad</addr-line>, <country>Iraq</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>School of Biosciences</institution>, <institution>College of Health and Life Sciences</institution>, <institution>Aston University</institution>, <addr-line>Birmingham</addr-line>, <country>United Kingdom</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Department of Chemistry and Biochemistry</institution>, <institution>College of Medicine</institution>, <institution>University of Kerbala</institution>, <addr-line>Karbala</addr-line>, <country>Iraq</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/566928/overview">Farooq Sher</ext-link>, Nottingham Trent University, United Kingdom</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1790057/overview">Lizie Daniela Tentler Prola</ext-link>, Independent Researcher, Greenville, NC, United States</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/501506/overview">Ivana Aleksic</ext-link>, University of Belgrade, Serbia</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1918415/overview">Hadia Almahli</ext-link>, University of Cambridge, United Kingdom</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Zaid Al-Obaidi, <email>z.alobaidi1@aston.ac.uk</email>
</corresp>
<fn fn-type="other" id="fn1">
<label>
<sup>&#x2020;</sup>
</label>
<p>ORCID: Zaid Al-Obaidi, <ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0003-3488-4572">https://orcid.org/0000-0003-3488-4572</ext-link>
</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>07</day>
<month>09</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>10</volume>
<elocation-id>1255955</elocation-id>
<history>
<date date-type="received">
<day>10</day>
<month>07</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>21</day>
<month>08</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2023 Alasadi and Al-Obaidi.</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Alasadi and Al-Obaidi</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Nowadays, various factors enhance the resistance of some microbes to antibiotics. Irrational antibiotic use is considered an example of such factors. Therefore, the synthesis and reporting of heterocyclic compounds with multiple biological properties are of considerable value. Ciprofloxacin is an antibiotic used to treat infections. New amidification and esterification derivatives of ciprofloxacin were synthesized. Their structure was identified and confirmed using both proton and carbon-13 nuclear magnetic resonance, mass spectrometry, and elemental analysis. With the employment of MTT (3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyl-terazoliumbromide) methods, <italic>in vitro</italic> anticancer activity was evaluated. The utilization of clinical and laboratory standards institute (CLSI) instructions was involved in the <italic>in vitro</italic> antimicrobial activity evaluation of the newly synthesized derivatives. In terms of anticancer activity, cell proliferation, viability, and IC<sub>50</sub>, as well as antimicrobial activities, IZD (Inhibition Zone Diameter), MIC (Minimum Inhibitory Concentrations), MBC (Minimum Bactericidal Concentrations), and MFC (Minimum Fungicidal Concentration) were measured and reported. The lowest cell proliferation and viability and IC<sub>50</sub> for 2,3-dihydroxypropyl 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylate (compound 5) were observed to be 27.12% and 7.83&#xa0;&#x3bc;g/mL. In antimicrobial activity, the lowest MIC for 2,3-dihydroxypropyl 7-(4-benzoylpiperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate (compound 6c) was observed to be 2&#xa0;&#x3bc;g/mL (against <italic>Proteus mirabilis</italic>) and the lowest MIC for 1-cyclopropyl-6-fluoro-7-(4-(4-(methylthio)benzoyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (compound 3d) was observed to be 32&#xa0;&#x3bc;g/mL (against <italic>Candida</italic> albicans, Aspergillus fumigatus). The effects were compared with commercially available drugs, and it was observed that some derivatives have the same efficacy as abemaciclib, which is used to treat breast cancer. Some derivatives were more effective than Cefazolin and Tolnaftate, well-known antibiotics and antifungals, respectively. Finally, a fairly clear relationship between the structure of the derivatives and their biological effectiveness was observed.</p>
</abstract>
<kwd-group>
<kwd>ciprofloxacin</kwd>
<kwd>amidification</kwd>
<kwd>esterification</kwd>
<kwd>anticancer</kwd>
<kwd>antimicrobial</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Biomaterials and Bio-Inspired Materials</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1">
<title>1 Introduction</title>
<p>A wide variety of antibiotics are used for various diseases every day worldwide. Unfortunately, the rate of improper utilization of antibiotics is increasing (<xref ref-type="bibr" rid="B32">Terreni et al., 2021</xref>) and this has led to the resistance of pathogenic microbial strains to many known antibiotics (<xref ref-type="bibr" rid="B35">Xiao et al., 2022</xref>). For this reason, there have been reports of modification to and changing the structure of antibiotics and the synthesis of new compounds (<xref ref-type="bibr" rid="B5">Das et al., 2020</xref>; <xref ref-type="bibr" rid="B24">Qu et al., 2023</xref>). For example, manganese ferrite&#x2013;modified biochar from vinasse has been reported for enhanced adsorption of fluoroquinolone antibiotics. The fluoroquinolones kill bacteria by preventing DNA replication. Generally, the fluoroquinolone antibiotic inhibits the ligase activity of type II topoisomerases. With the ligase activity disrupted, DNA with single- and double-strand breaks lead to cell death (<xref ref-type="bibr" rid="B1">Aldred et al., 2014</xref>). In another proposed mechanism, fluoroquinolone antibiotics cause the oxidation of guanine nucleotides in the bacterial nucleotide pool, which contributes to their cytotoxicity (<xref ref-type="bibr" rid="B38">Foti et al., 2012</xref>). Delafloxacin, gemifloxacin, levofloxacin, moxifloxacin, and norfloxacin (<xref ref-type="fig" rid="F1">Figure 1</xref>) are other examples of fluoroquinolone antibiotics (<xref ref-type="bibr" rid="B12">Hooper, 2001</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Common fluoroquinolone antibiotics.</p>
</caption>
<graphic xlink:href="fmats-10-1255955-g001.tif"/>
</fig>
<p>Ciprofloxacin is a fluoroquinolone antibiotic. Ciprofloxacin is an antibiotic used to treat infections, including joint and bone infections, intra-abdominal infections, certain types of infectious diarrhea, respiratory tract infections, skin infections, typhoid fever, and urinary tract infections. In the structure of some fluoroquinolone antibiotics such as ciprofloxacin, levofloxacin, and norfloxacin, two heterocyclic compounds of 1,4-dihydroquinoline and piperazine are present (<xref ref-type="bibr" rid="B37">Zhanel et al., 2006</xref>; <xref ref-type="bibr" rid="B33">Uncu et al., 2019</xref>; <xref ref-type="bibr" rid="B16">Kudiyarova et al., 2021</xref>). The bicyclic heterocyclic compound of quinoline consists of a benzene ring connected with a pyridine ring. Derivatives of quinoline are abundantly found in nature, such as Galipea, Cinchona, Papaver, etc. In addition to Ciprofloxacin, commercial drugs such as Tacrine, Mefloquine, Bosutinib, etc., (<xref ref-type="fig" rid="F2">Figure 2</xref>). Have quinoline derivatives in their structure.</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Some drugs containing quinoline derivatives.</p>
</caption>
<graphic xlink:href="fmats-10-1255955-g002.tif"/>
</fig>
<p>Several other biological properties of quinoline-containing heterocyclic compounds have been reported (<xref ref-type="bibr" rid="B17">Matada et al., 2021</xref>). Some biological properties, such as anti-bacterial and anti-fungal activity (<xref ref-type="bibr" rid="B6">Dib et al., 2021</xref>; <xref ref-type="bibr" rid="B15">Jamshidi et al., 2022</xref>), anti-cancer activity (<xref ref-type="bibr" rid="B11">Gao et al., 2019</xref>), anti-plasmodial activities (<xref ref-type="bibr" rid="B27">Sharma et al., 2023</xref>), etc., have been reported from compounds containing this heteroatom. For example, in 2021, sulfur-containing quinoline derivatives (<xref ref-type="fig" rid="F3">Figure 3</xref>) were reported that were effective against bacterial species such as <italic>S. pneumonia, B. subtilis</italic>, and <italic>E. coli</italic> (<xref ref-type="bibr" rid="B8">El-Shershaby et al., 2021</xref>).</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Sulfur-containing quinoline derivatives with antibacterial activity.</p>
</caption>
<graphic xlink:href="fmats-10-1255955-g003.tif"/>
</fig>
<p>Benzothiazolyl quinolone derivatives (<xref ref-type="fig" rid="F4">Figure 4</xref>) are another polycyclic heterocyclic compounds that were reported in 2021 as newly synthesized heterocyclic structures effective against <italic>E. coli</italic> and <italic>P. aeruginosia</italic> bacterial species (<xref ref-type="bibr" rid="B4">Bolakatti et al., 2021</xref>).</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Sulfur-containing quinoline derivatives with antibacterial activity.</p>
</caption>
<graphic xlink:href="fmats-10-1255955-g004.tif"/>
</fig>
<p>Pyrazine is another bioactive compound that (<xref ref-type="bibr" rid="B10">Ferreira and Kaiser, 2012</xref>), in addition to Ciprofloxacin, is also present in the structure of Bosutinib. Medicines such as pyrazinamide (<xref ref-type="fig" rid="F5">Figure 5</xref>), paritaprevir, bortezomib, amiloride, etc., have a pyrazine in their structure (<xref ref-type="bibr" rid="B14">Huigens et al., 2022</xref>; <xref ref-type="bibr" rid="B30">Tambat et al., 2022</xref>). Other pharmacological activities, such as anti-inflammatory activity (<xref ref-type="bibr" rid="B28">Shashikant et al., 2022</xref>), antimicrobial activity (<xref ref-type="bibr" rid="B25">Schneider et al., 2022</xref>), anti-cancer activity (<xref ref-type="bibr" rid="B31">Tantawy et al., 2020</xref>), etc., have been reported from synthetic compounds containing pyrazine.</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>Some drugs containing pyrazine derivatives.</p>
</caption>
<graphic xlink:href="fmats-10-1255955-g005.tif"/>
</fig>
<p>Considering the biological properties of Ciprofloxacin, as discussed, amidification and esterification of ciprofloxacin can be performed and compounds developed with biological properties. In this study, the derivatives mentioned above were synthesized and studied on various Gram-positive and Gram-negative pathogenic bacterial agents and common pathogenic bacterial strains between aquatic animals and humans. <italic>In vitro</italic> biological studies of the synthetic compounds were also evaluated on breast cancer cells and bacterial cultures. The results of these <italic>in vitro</italic> tests showed that the synthesized amidification and esterification derivatives of ciprofloxacin have high antimicrobial and anticancer activities. By performing other supplementary tests in subsequent studies, such as <italic>in silico</italic> studies, <italic>in vivo</italic> tests, cytotoxicity texts, etc., and if the results are acceptable, amidification and esterification derivatives of ciprofloxacin can be suitable candidates for developing effective antibiotic and anticancer drugs.</p>
</sec>
<sec id="s2">
<title>2 Experimental</title>
<sec id="s2-1">
<title>2.1 Chemicals and reagents</title>
<p>All solvents, chemicals, and consumables utilized in this study were obtained from Merck Millipore and Sigma-Aldrich.</p>
</sec>
<sec id="s2-2">
<title>2.2 Amidification of ciprofloxacin</title>
<p>An accurately weighed amount of 10&#xa0;mmol Acyl chloride derivatives was added to a stirring mixture of 1.84&#xa0;g of ciprofloxacin hydrochloride (5&#xa0;mmol) and 2.65&#xa0;g of Na<sub>2</sub>CO<sub>3</sub> in 20&#xa0;mL of tetrahydrofuran at 0&#xb0;C (<xref ref-type="table" rid="T1">Table 1</xref>). The resultant mixture was continuously stirred for 1&#xa0;h at 0&#xb0;C. Thereafter, a yellow precipitate was observed. The column chromatography method (silica gel 60&#x2013;120 mesh, a gradient solvent system of 0&#x2013;20%methanol/DCM) was used for the purification of the synthesized derivatives.</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>Synthesized ciprofloxacin amidification derivatives.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="center">Derivative</th>
<th align="center">R (2a-d)</th>
<th align="center">Final structure</th>
<th align="center">Efficiency (%)</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="center">3a</td>
<td align="center">2a: acetyl chloride</td>
<td align="center">
<inline-graphic xlink:href="FMATS_fmats-2023-1255955_wc_tfx1.tif"/>
</td>
<td align="center">88</td>
</tr>
<tr>
<td align="center">3b</td>
<td align="center">2b: pivaloyl chloride</td>
<td align="center">
<inline-graphic xlink:href="FMATS_fmats-2023-1255955_wc_tfx2.tif"/>
</td>
<td align="center">89</td>
</tr>
<tr>
<td align="center">3c</td>
<td align="center">2c: benzoyl chloride</td>
<td align="center">
<inline-graphic xlink:href="FMATS_fmats-2023-1255955_wc_tfx3.tif"/>
</td>
<td align="center">86</td>
</tr>
<tr>
<td align="center">3d</td>
<td align="center">2d: 4-(methylthio)benzoyl chloride</td>
<td align="center">
<inline-graphic xlink:href="FMATS_fmats-2023-1255955_wc_tfx4.tif"/>
</td>
<td align="center">84</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>7-(4-acetylpiperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (3a).</p>
<p>MS <italic>m/z</italic> 373 (M<sup>&#x2b;</sup>). Element analysis. Calcd for C<sub>19</sub>H<sub>20</sub>FN<sub>3</sub>O<sub>4</sub>: C, 61.12. H, 5.40. N, 11.25. O, 17.14. Found: C, 61.15. H, 5.38. N, 11.24. O, 17.17. <sup>1</sup>H NMR (DMSO-d6) <italic>&#x3b4;</italic> &#x3d; 1.05-4.07 (m, 2H), 1.38-1.42 (m, 2H), 2.18 (s, 3H), 3.36 (t, J &#x3d; 8.0&#xa0;Hz, 4H), 3.62 (t, J &#x3d; 8.0&#xa0;Hz, 4H), 4.21-4.25 (m, 1H), 6.17 (s, 1H), 7.86 (s, 1H), 8.25 (s, 1H), 12.37 (s, 1H). <sup>13</sup>C NMR (DMSO-d6) <italic>&#x3b4;</italic> &#x3d; 7.8, 21.9, 36.4, 44.7, 52.8, 103.2, 109.5, 111.3, 116.1, 135.8, 146.1, 147.8, 152.4, 165.4, 168.7, 177.3.</p>
<p>1-cyclopropyl-6-fluoro-4-oxo-7-(4-pivaloylpiperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid (3b).</p>
<p>MS <italic>m/z</italic> 415 (M<sup>&#x2b;</sup>). Element analysis. Calcd for C<sub>22</sub>H<sub>26</sub>FN<sub>3</sub>O<sub>4</sub>: C, 63.60. H. 6.31. N, 10.11. O, 15.40. Found: C, 63.62. H, 6.38. N, 10.10. O, 15.46. <sup>1</sup>H NMR (DMSO-d6) <italic>&#x3b4;</italic> &#x3d; 1.04, 1.08 (m, 2H), 1.25 (s, 9H), 1.35-1.39 (m, 2H), 3.31 (t, J &#x3d; 7.5&#xa0;Hz, 4H), 3.57 (t, J &#x3d; 8.0&#xa0;Hz, 4H), 4.15-4120 (m, 1H), 6.09 (s, 1H), 7.82 (s, 1H), 8.17 (s, 1H), 12.32 (s, 1H). <sup>13</sup>C NMR (DMSO-d6) <italic>&#x3b4;</italic> &#x3d; 7.5, 28.3, 35.8, 38.3, 45.1, 53.2, 102.6, 109.7, 112.4, 115.8, 134.9, 147.3, 148.4, 152.7, 165.7, 176.3, 177.5.</p>
<p>7-(4-benzoylpiperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (3c).</p>
<p>MS <italic>m/z</italic> 435 (M<sup>&#x2b;</sup>). Element analysis. Calcd for C<sub>24</sub>H<sub>22</sub>FN<sub>3</sub>O<sub>4</sub>: C, 66.20. H, 5.09. N, 9.65. O, 14.70. Found: C, 66.18. H, 5.07. N, 9.69. O, 14.69. <sup>1</sup>H NMR (DMSO-d6) <italic>&#x3b4;</italic> &#x3d; 1.01-1.05 (m, 2H), 1.32-1.40 (m, 2H), 3.28 (t, J &#x3d; 8&#xa0;Hz, 4H), 3.47 (t, J &#x3d; 8.4 Hz, 4H), 4.12-4.17 (m, 1H), 6.04 (s, 1H), 7.52-7.58 (m, 3H), 7.96-8.05 (m, 3H), 8.24 (s, 1H), 12.42 (s, 1H). <sup>13</sup>C NMR (DMSO-d6) <italic>&#x3b4;</italic> &#x3d; 7.1, 35.4, 49.6, 52.9, 101.9, 109.3, 112.7, 115.3, 126.7, 128.1, 129.5, 134.3, 135.2, 146.9, 148.1, 152.3, 166.3, 168.6, 177.9.</p>
<p>1-cyclopropyl-6-fluoro-7-(4-(4-(methylthio)benzoyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (3d).</p>
<p>MS <italic>m/z</italic> 481 (M<sup>&#x2b;</sup>). Element analysis. Calcd for C<sub>25</sub>H<sub>24</sub>FN<sub>3</sub>O<sub>4</sub>S: C, 62.36. H, 5.02. N, 8.73. S, 6.66. Found: C, 62.35. H, 5.05. N, 8.70. S, 6.69. <sup>1</sup>H NMR (DMSO-d6) <italic>&#x3b4;</italic> &#x3d; 1.02-1.06 (m, 2H), 1.27-1.35 (m, 2H), 2.46 (s, 1H), 3.24 (t, J &#x3d; 8.5 Hz, 4H), 3.41 (t, J &#x3d; 8.5&#xa0;Hz, 4H), 4.14-4.21 (m, 1H), 6.10 (s, 1H), 7.55 (d, J &#x3d; 8.4&#xa0;Hz, 2H), 7.91-7.99 (m, 3H), 8.41 (s, 1H), 12.36 (s, 1H). <sup>13</sup>C NMR (DMSO-d6) <italic>&#x3b4;</italic> &#x3d; 7.7, 14.9, 34.8, 50.1, 53.4, 101.5, 109.1, 112.4, 115.6, 126.1, 128.4, 132.9, 134.8, 140.2, 146.4, 149.9, 153.1, 165.9, 167.8, 178.1.</p>
</sec>
<sec id="s2-3">
<title>2.3 Esterification and amidification of ciprofloxacin</title>
<p>A total of 14.7&#xa0;g of ciprofloxacin hydrochloride (40&#xa0;mmol) was dissolved in 40&#xa0;mL of tetrahydrofuran and then 11.1&#xa0;g of glycerol (120&#xa0;mmol) was added to the solution (<xref ref-type="table" rid="T2">Table 2</xref>). The mixture stirred and concentrated H<sub>2</sub>SO<sub>4</sub> (2&#xa0;mL) was added dropwise. Thereafter, the mixture was refluxed for 4&#xa0;h at 110&#xb0;C. The column chromatography method (silica gel 60&#x2013;120 mesh, a gradient solvent system of 0%&#x2013;20% methanol/DCM) was used for the purification of the synthesized compounds.</p>
<table-wrap id="T2" position="float">
<label>TABLE 2</label>
<caption>
<p>Synthesized ciprofloxacin esterification/amidification derivatives.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="center">Derivative</th>
<th align="center">R (2a-c)</th>
<th align="center">Final structure</th>
<th align="center">Efficiency (%)</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="center">5</td>
<td align="center">-</td>
<td align="center">
<inline-graphic xlink:href="FMATS_fmats-2023-1255955_wc_tfx5.tif"/>
</td>
<td align="center">86</td>
</tr>
<tr>
<td align="center">6a</td>
<td align="center">2a: acetyl chloride</td>
<td align="center">
<inline-graphic xlink:href="FMATS_fmats-2023-1255955_wc_tfx6.tif"/>
</td>
<td align="center">89</td>
</tr>
<tr>
<td align="center">6b</td>
<td align="center">2b: pivaloyl chloride</td>
<td align="center">
<inline-graphic xlink:href="FMATS_fmats-2023-1255955_wc_tfx7.tif"/>
</td>
<td align="center">85</td>
</tr>
<tr>
<td align="center">6c</td>
<td align="center">2c: benzoyl chloride</td>
<td align="center">
<inline-graphic xlink:href="FMATS_fmats-2023-1255955_wc_tfx8.tif"/>
</td>
<td align="center">86</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>2,3-dihydroxypropyl 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylate (5).</p>
<p>MS <italic>m/z</italic> 405 (M<sup>&#x2b;</sup>). Element analysis. Calcd for C<sub>20</sub>H<sub>24</sub>FN<sub>3</sub>O<sub>5</sub>: C, 59.25. H, 5.97. N, 10.36. O, 19.73. Found: C, 21.18. H, 5.96. N, 10.33. O, 19.68. <sup>1</sup>H NMR (DMSO-d6) <italic>&#x3b4;</italic> &#x3d; 1.03-1.09 (m, 3H), 1.29-1.34 (m, 2H), 2.75-2.79 (m, 4H), 3.44-3.52 (m, 6H), 3.98 (s, 1H), 4.12-4.31 (m, 4H), 5.73 (s, 1H), 6.08 (s, 1H), 7.99 (s, 1H), 8.57 (s, 1H). <sup>13</sup>C NMR (DMSO-d6) <italic>&#x3b4;</italic> &#x3d; 7.1, 35.5, 45.4, 51.2, 63.0, 67.6, 71.1, 102.7, 110.2, 119.9, 115.3, 134.6, 144. 147.5, 152.2, 165.8, 171.4.</p>
<p>An accurately weighed amount of 60&#xa0;mmol Acyl chloride derivatives was added to a stirring mixture of 8.1g of compound 2,3-dihydroxypropyl 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylate (20&#xa0;mmol) and 10.5g of Na<sub>2</sub>CO<sub>3</sub> in 40&#xa0;mL of tetrahydrofuran at 0&#xb0;C. The resultant solution was continuously stirred for 1&#xa0;h at 0&#xb0;C. The column chromatography method (silica gel 60&#x2013;120 mesh, isocratic solvent system of 1:4 methanol/DCM) was used for the purification of the synthesized derivatives.</p>
<p>2,3-dihydroxypropyl 7-(4-acetylpiperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate (6a).</p>
<p>MS <italic>m/z</italic> 447 (M<sup>&#x2b;</sup>). Element analysis. Calcd for C<sub>22</sub>H<sub>26</sub>FN<sub>3</sub>O<sub>6</sub>: C, 59.05. H, 5.86. N, 9.39. O, 21.45. Found: C, 59.04. H, 5.85. N, 9.41. O, 21.44. <sup>1</sup>H NMR (DMSO-d6) <italic>&#x3b4;</italic> &#x3d; 1.01-1.05 (m, 2H), 1.30-1.33 (m, 2H), 2.14 (s, 1H), 3.31 (t, J &#x3d; 8Hz, 4H), 3.53-3.57 (m, 6H), 3.65 (s, 1H), 4.15-4.35 (m, 4H), 5.79 (s, 1H), 6.03 (s, 1H), 8.02 (s, 1H), 8.62 (s, 1H). <sup>13</sup>C NMR (DMSO-d6) <italic>&#x3b4;</italic> &#x3d; 7.4, 21.9, 35.2, 46.7, 51.6, 63.5, 67.1, 71.9, 102.1, 110.3, 112.6, 115.0, 134.1, 144.6, 146.9, 152.5, 165.5, 167.4, 171.9.</p>
<p>2,3-dihydroxypropyl 1-cyclopropyl-6-fluoro-4-oxo-7-(4-pivaloylpiperazin-1-yl)-1,4-dihydroquinoline-3-carboxylate (6b).</p>
<p>MS <italic>m/z</italic> 489 (M<sup>&#x2b;</sup>). Element analysis. Calcd for C<sub>25</sub>H<sub>32</sub>FN<sub>3</sub>O<sub>6</sub>: C, 61.34. H, 6.59. N, 8.58. O, 19.61. Found: C, 61.35. H, 6.62. N, 8.59. O, 19.62. <sup>1</sup>H NMR (DMSO-d6) <italic>&#x3b4;</italic> &#x3d; 1.03-1.09 (m, 2H), 1.23-1.35 (m, 3H), 3.28 (t, J &#x3d; 7.5 Hz, 4H), 3.52-3.59 (m, 6H), 3.77 (s, 1H), 4.12-4.36 (m, 4H), 5.75 (s, 1H), 6.10 (s, 1H), 8.12 (s, 1H), 8.76 (s, 1H). <sup>13</sup>C NMR (DMSO-d6) <italic>&#x3b4;</italic> &#x3d; 7.1, 27.3, 35.7, 38.2, 46.9, 53.5, 63.2, 67.7, 71.9, 101.9, 110.8, 112.1, 115.6, 134.6, 145.2, 147.6, 152.1, 165.1, 169.8, 172.9.</p>
<p>2,3-dihydroxypropyl 7-(4-benzoylpiperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate (6c).</p>
<p>MS <italic>m/z</italic> 509 (M<sup>&#x2b;</sup>). Element analysis. Calcd for C<sub>27</sub>H<sub>28</sub>FN<sub>3</sub>O<sub>6</sub>: C, 63.65. H, 5.54. N, 8.25. O, 18.84. Found: C, 63.70. H, 5.43. N, 8.28. O, 18.86. <sup>1</sup>H NMR (DMSO-d6) <italic>&#x3b4;</italic> &#x3d; 1.0-1.10 (m, 2H), 1.21-1.29 (m, 32), 3.33 (t, J &#x3d; 8.4 Hz, 4H), 3.55-3.62 (m, 6H), 3.84 (s, 1H), 4.11-4.31 (m, 4H), 5.79 (s, 1H), 6.05 (s, 1H), 7.63-7.84 (m, 5H), 8.70 (s, 1H). <sup>13</sup>C NMR (DMSO-d6) <italic>&#x3b4;</italic> &#x3d; 7.3, 34.9, 50.8, 53.1, 63.6, 67.1, 71.4, 10.2.3, 111.2, 116.4, 115.9, 127.2, 128.5, 129.9, 134.7, 135.1, 144.6, 147.8, 152.6, 165.4, 68.5, 171.3.</p>
</sec>
<sec id="s2-4">
<title>2.4 Anticancer activity tests</title>
<p>In the anticancer activity tests, the culture medium was Roswell Park Memorial Institute 1640 (RPMI), 10% Fetal Bovine Serum (FBS), and 200&#xa0;&#x3bc;L of antibiotic (G/streptomycin and penicillin). The test steps are as follows (<xref ref-type="bibr" rid="B19">Moghaddam-manesh et al., 2021</xref>; <xref ref-type="bibr" rid="B20">Moghaddam-Manesh and Hosseinzadegan, 2021</xref>):</p>
<p>First, breast cancer cells (MCF-7) were cultured in the culture medium. 200&#xa0;&#x3bc;L of MCF-7 with a density of 1.2 &#xd7; 10<sup>4</sup> cells per well was seeded in a microplate and incubated in suitable conditions. It should be noted that the suitable conditions were 5% CO<sub>2</sub>, 37&#xb0;C, and 24&#xa0;h. Then, concentrations of 6.25, 12.5, 25, and 50&#xa0;&#x3bc;g/mL of the derivatives were added to the wells and incubated for 24 and 48&#xa0;h under the above conditions. After the tested times (24 and 48&#xa0;h), the contents of the wells, including derivatives and culture medium, were emptied and 50&#xa0;&#x3bc;L of MTT solution and 150&#xa0;&#x3bc;L of culture medium were added to the wells and incubated in 5% CO<sub>2</sub>, 37&#xb0;C for 4&#xa0;h. Then, the culture medium and MTT were emptied and 200&#xa0;&#x3bc;L of dimethyl sulfoxide (DMSO) was added to the wells. Finally, the absorbance of the contents of the wells at 570&#xa0;nm was read using an ELISA reader.</p>
<p>In the test stages, at the same time as studying the derivatives, a culture medium without derivatives was used as a control. The test steps were carried out on abemaciclib, a well-known commercial MCF-7 breast cancer cells drug, to compare the properties of the compounds. It should be noted that the MTT solution contained 2&#xa0;&#x3bc;g/mL of MTT in phosphate-buffered saline (PBS).</p>
</sec>
<sec id="s2-5">
<title>2.5 Antimicrobial activity tests</title>
<p>In antimicrobial activity tests of the synthesized derivatives for antibacterial activity, IZD, MIC, and MBC were evaluated, whereas for the antifungal activity, IZD, MIC, and MFC were evaluated. The guidelines of CLSI (the Clinical and laboratory standards institute, guidelines M07-A9, M26-A, M27-A2) were used in all the tests (<xref ref-type="bibr" rid="B9">Etemadi et al., 2016</xref>; <xref ref-type="bibr" rid="B3">Beyzaei et al., 2017</xref>). Mueller Hinton Broth and Mueller Hinton Agar were used for the antibacterial tests and Dextrose Tryptone Broth and Dextrose Tryptone Agar were used as culture media for the antifungal tests. It should be noted that the final results are the average of the results of three repetitions of the test. The test steps are as follows (<xref ref-type="bibr" rid="B3">Beyzaei et al., 2017</xref>; <xref ref-type="bibr" rid="B18">Moghaddam-Manesh et al., 2020</xref>):</p>
<p>First, using a spectrophotometer, a concentration of 1 &#xd7; 10<sup>5</sup> colony-forming unit/mL (CFU/mL) of bacterial and fungal species was prepared in a broth culture medium. Then, concentrations of 1&#x2013;2,048&#xa0;&#x3bc;g/mL (1, 2, 4, 8, 16, and 2,048&#xa0;&#x3bc;g/mL) of the derivatives were prepared in DMSO.</p>
<p>To obtain MIC, 100&#xa0;&#x3bc;L of the derivatives, 100&#xa0;&#x3bc;L of the broth culture medium, and 10&#xa0;&#x3bc;L of the studied bacterial or fungal species were added to a microplate (96 well plates). Then, it was placed in a shaker incubator for a suitable time and at a suitable temperature and was slowly stirred. After the necessary time, turbidity in the well indicated growth and transparency a lack of growth. Here, we define the MIC as the first concentration after which turbidity was observed. It should be noted that the proper time for the MIC test is 48&#xa0;h and the proper temperature for bacterial species is 37&#xb0;C and is 27&#xb0;C for fungal species.</p>
<p>To obtain MBC and MFC, the contents of the MIC concentration and three more concentrated concentrations were cultured on the agar culture medium and placed inside the incubator at the proper time and temperature. Then, the concentration at which bacterial or fungal species did not grow was reported as MBC or MFC. It should be noted that the appropriate time for the MBC and MFC tests is 72&#xa0;h and the proper temperature for bacterial species is 37&#xb0;C and is 27&#xb0;C for fungal species.</p>
<p>To obtain IZD, the studied bacterial or fungal species were first cultured on an agar medium. Then, a disc blank was placed on them. A total of 10&#xa0;&#x3bc;L of the concentration obtained for the MIC of the derivatives was injected on the disk blanks and was placed inside the incubator at the right time and temperature. Finally, the diameter of the halo created by the caliper was measured and reported. It should be noted that the appropriate time for the IZD test is 24&#xa0;h and the proper temperature for bacterial species is 37&#xb0;C and is 27&#xb0;C for fungal species.</p>
<p>In the test stages, at the same time as studying the derivatives, the solvent (DMSO) without derivatives was used as a control. The test steps were carried out on several well-known commercial antibacterial and antifungal drugs to compare the properties of the compounds.</p>
</sec>
</sec>
<sec sec-type="results|discussion" id="s3">
<title>3 Results and discussion</title>
<sec id="s3-1">
<title>3.1 Amidification and esterification of ciprofloxacin</title>
<p>As mentioned in the introduction, in this study, considering the bioactivity of ciprofloxacin, its amidification derivatives and esterification/amidification derivatives were synthesized and their biological properties were tested. As shown in <xref ref-type="fig" rid="F6">Figure 6</xref>, from the reaction of ciprofloxacin with acyl chloride derivatives, ciprofloxacin/ciprofloxacin/amidification derivatives were synthesized. The reaction was carried out in the presence of Na<sub>2</sub>CO<sub>3</sub> as a Br&#xf8;nsted&#x2013;Lowry base. The structure of the derivatives was confirmed using proton nuclear magnetic resonance (<sup>1</sup>H NMR), carbon-13 nuclear magnetic resonance (<sup>13</sup>C NMR), mass spectrometry (MS), and elemental analysis (EA), the results of which are given in <xref ref-type="sec" rid="s2">Sections 2</xref>, <xref ref-type="sec" rid="s3">3</xref>.</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>Synthesis of ciprofloxacin amidification derivatives.</p>
</caption>
<graphic xlink:href="fmats-10-1255955-g006.tif"/>
</fig>
<p>The advantages of the synthesis of the ciprofloxacin/amidification derivatives studied in this research include the synthesis of new derivatives, the use of Na<sub>2</sub>CO<sub>3</sub> as a green catalyst, and the high efficiency of the derivatives, as shown in <xref ref-type="fig" rid="F6">Figure 6</xref>.</p>
<p>Esterification/amidification derivatives of ciprofloxacin were synthesized (<xref ref-type="fig" rid="F7">Figure 7</xref>). For this purpose, first, an esterification reaction using ciprofloxacin and glycerol in the presence of sulfuric acid as Br&#xf8;nsted&#x2013;Lowry acid was carried out. Then, the esterified ciprofloxacin was amidified under the aforementioned conditions and using Na<sub>2</sub>CO<sub>3</sub>.</p>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption>
<p>Synthesis of ciprofloxacin esterification/amidification derivatives.</p>
</caption>
<graphic xlink:href="fmats-10-1255955-g007.tif"/>
</fig>
<p>The high efficiency of the derivatives and the greenness of Na<sub>2</sub>CO<sub>3</sub> can also be expressed here. By using <sup>1</sup>H NMR, <sup>13</sup>C NMR, MS, and EA, the synthesized esterification/amidification derivatives of ciprofloxacin were identified and confirmed.</p>
</sec>
<sec id="s3-2">
<title>3.2 Examination of anticancer activities</title>
<p>The anticancer activity of the synthesized derivatives and abemaciclib was tested on breast cancer cells (MCF-7). Abemaciclib, a known breast cancer drug, was used to compare the anticancer properties of the compounds. As mentioned in paragraphs 2&#x2013;5, concentrations of 6.25, 12.5, 25, and 50&#xa0;&#x3bc;g/mL of abemaciclib and compounds were investigated for 24 and 48&#xa0;h. In the evaluations, the cell proliferation and viability were obtained at different concentrations for 24 and 48 h, and, finally, the IC<sub>50</sub> value was reported (<xref ref-type="fig" rid="F8">Figure 8</xref>).</p>
<fig id="F8" position="float">
<label>FIGURE 8</label>
<caption>
<p>Cell proliferation and viability of abemaciclib, 3a, 3b, 3c, 3d, 5, 6a, 6b, and 6c at different concentrations and after 24 and 48&#xa0;h (<italic>n</italic> &#x3d; 3), &#xb1;SD.</p>
</caption>
<graphic xlink:href="fmats-10-1255955-g008.tif"/>
</fig>
<p>After 24&#xa0;h and at a concentration of 50&#xa0;&#x3bc;g/mL, the cell proliferation and viability for abemaciclib, 3a, 3b, 3c, 3d, 5, 6a, 6b, and 6c were determined to be 35.54%, 42.94%, 41.67%, 44.44%, 40.51%, 34.86%, 34.91%, 35.01%, and 35.99%, respectively, compared to the control. After 48&#xa0;h and at a concentration of 50&#xa0;&#x3bc;g/mL, the cell proliferation and viability for abemaciclib and 3a, 3b, 3c, 3d, 5, 6a, 6b, and 6c were determined to be 27.52%, 37.53%, 35.76%, 38.37%, 37.01%, 27.12%, 27.34%, 29.18%, and 27.19%, respectively, compared to the control. The results showed that in both times (24 and 48&#xa0;h), in the abemaciclib and synthesized derivatives, the highest cell proliferation and viability is at the concentration of 50&#xa0;&#x3bc;g/mL. Moreover, the effectiveness of abemaciclib and the derivatives, based on cell proliferation and viability, was higher after 48&#xa0;h than 24&#xa0;h.</p>
<p>The IC<sub>50</sub> values after 48&#xa0;h for abemaciclib, 3a, 3b, 3c, 3d, 5, 6a, 6b, and 6c were determined to be 7.95&#xa0;&#x3bc;g/mL, 22.61&#xa0;&#x3bc;g/mL, 22.37&#xa0;&#x3bc;g/mL, 26.15&#xa0;&#x3bc;g/mL, 21.62&#xa0;&#x3bc;g/mL, 7.83&#xa0;&#x3bc;g/mL, 8.36&#xa0;&#x3bc;g/mL, 8.49&#xa0;&#x3bc;g/mL, and 8.96&#xa0;&#x3bc;g/mL, respectively.</p>
<p>The results show that the highest anticancer property was found in 5, and that the anticancer properties of ciprofloxacin esterification/amidification derivatives (6a, 6b, and 6c) are higher than ciprofloxacin amidation derivatives (3a, 3b, 3c, and 3d). A review of the literature shows that glycerin can increase anticancer properties (<xref ref-type="bibr" rid="B22">Pruchnik et al., 2016</xref>; <xref ref-type="bibr" rid="B34">Wang et al., 2018</xref>). Therefore, based on the structure of 5, ciprofloxacin esterification/amidification derivatives, and ciprofloxacin amidation derivatives, it can be concluded that the esterification of ciprofloxacin due to the addition of glycerol increases the anticancer property. Regarding the obtained results, it was found that the anticancer properties of compound 5 and ciprofloxacin derivatization (esterification/amidation) were close to each other. Moreover, the anticancer property of ciprofloxacin amidation is almost the same. Thus, it can be concluded that the groups binding to the pyrazole ring do not play an essential role in the anticancer properties of the products.</p>
<p>Based on the values of cell proliferation and viability, as well as IC<sub>50</sub> related to 5 and abemaciclib, it was found that the anticancer property of 5 is slightly higher than abemaciclib, which is a known anti-breast cancer drug.</p>
<p>Statistical studies were performed for abemaciclib, 3a, 3b, 3c, 3d, 5, 6a, 6b, and 6c at 24 h and 48&#xa0;h and IC<sub>50</sub> values; <italic>p</italic>-values were obtained, and the results are shown in <xref ref-type="table" rid="T3">Table 3</xref>.</p>
<table-wrap id="T3" position="float">
<label>TABLE 3</label>
<caption>
<p>Statistical studies of synthesized derivatives.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th colspan="2" align="left"/>
<th align="left">Abemaciclib</th>
<th align="left">3a</th>
<th align="left">3b</th>
<th align="left">3c</th>
<th align="left">3d</th>
<th align="left">5</th>
<th align="left">6a</th>
<th align="left">6b</th>
<th align="left">6c</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td rowspan="2" align="center">
<italic>p</italic>-values</td>
<td align="left">24 (h)</td>
<td align="left">0.001</td>
<td align="left">0.001</td>
<td align="left">0.000</td>
<td align="left">0.004</td>
<td align="left">0.003</td>
<td align="left">0.001</td>
<td align="left">0.000</td>
<td align="left">0.003</td>
<td align="left">0.001</td>
</tr>
<tr>
<td align="left">48 (h)</td>
<td align="left">0.000</td>
<td align="left">0.003</td>
<td align="left">0.002</td>
<td align="left">0.001</td>
<td align="left">0.000</td>
<td align="left">0.000</td>
<td align="left">0.004</td>
<td align="left">0.000</td>
<td align="left">0.001</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Based on the results shown in the Table, it can be concluded that concentration is a critical parameter at 24 and 48&#xa0;h. Therefore, the IC<sub>50</sub> values and the effectiveness of the compounds depend on the exposure time.</p>
<p>As a final result, it can be said that 5 has the ability to be used as an effective anticancer drug against breast cancer, and, after other supplementary tests, it can be developed as a potent drug (<xref ref-type="fig" rid="F9">Figure 9</xref>).</p>
<fig id="F9" position="float">
<label>FIGURE 9</label>
<caption>
<p>The most effective synthesized structure with anticancer activity [compound (5)].</p>
</caption>
<graphic xlink:href="fmats-10-1255955-g009.tif"/>
</fig>
</sec>
<sec id="s3-3">
<title>3.3 Examination of antimicrobial activities</title>
<p>The antimicrobial properties of the synthesized derivatives along with drugs 1 and 2 were investigated on four Gram-positive strains (ATCC11778/<italic>Bacillus cereus</italic>, ATCC15352/<italic>Streptococcus equinus</italic>, ATCC25729/<italic>Rhodococcus equi</italic>, and ATCC29213/<italic>Staphylococcus aureus</italic>), four Gram-negative strains (ATCC7002/<italic>Proteus mirabilis</italic>, ATCC19606/<italic>Acinetobacter baumannii</italic>, ATCC9610/<italic>Yersinia enterocolitica</italic>, and ATCC25922/<italic>Escherichia coli</italic>) and two fungal species (ATCC10231/<italic>Candida albicans</italic> and ATCC1022/<italic>Aspergillus fumigatus Fresenius</italic>). The results of the antimicrobial activity of the synthesized compounds, Gentamicin, Cefazolin, Terbinafine, and Tolnaftate, including the MIC value, MBC/MFC value, and IZD value, are shown in <xref ref-type="table" rid="T4">Tables 4</xref>&#x2013;<xref ref-type="table" rid="T6">6</xref>.</p>
<table-wrap id="T4" position="float">
<label>TABLE 4</label>
<caption>
<p>MIC value (&#x3bc;g/mL) results in investigating the antimicrobial properties of the synthesized derivatives.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th rowspan="2" align="center">Compound</th>
<th colspan="4" align="center">Gram-positive pathogenic bacterial</th>
<th colspan="4" align="center">Gram-negative pathogenic bacterial</th>
<th colspan="2" align="center">Fungi strain</th>
</tr>
<tr>
<th align="center">ATCC 11778 <italic>Bacillus</italic> cereus</th>
<th align="center">ATCC 15352 <italic>Streptococcus</italic> equinus</th>
<th align="center">ATCC 25729 Rhodococcus equi</th>
<th align="center">ATCC 29213 <italic>Staphylococcus aureus</italic>
</th>
<th align="center">ATCC 7002 <italic>Proteus mirabilis</italic>
</th>
<th align="center">ATCC 19606 <italic>Acinetobacter</italic> baumannii</th>
<th align="center">ATCC 9610 <italic>Yersinia</italic> enterocolitica</th>
<th align="center">ATCC 25922 <italic>Escherichia coli</italic>
</th>
<th align="center">ATCC 10231 <italic>Candida</italic> albicans</th>
<th align="center">ATCC 1022 Aspergillus fumigatus Fresenius</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="center">3a</td>
<td align="center">512</td>
<td align="center">512</td>
<td align="center">-</td>
<td align="center">-</td>
<td align="center">1024</td>
<td align="center">-</td>
<td align="center">2048</td>
<td align="center">1024</td>
<td align="center">-</td>
<td align="center">512</td>
</tr>
<tr>
<td align="center">3b</td>
<td align="center">512</td>
<td align="center">256</td>
<td align="center">-</td>
<td align="center">-</td>
<td align="center">512</td>
<td align="center">-</td>
<td align="center">1024</td>
<td align="center">512</td>
<td align="center">-</td>
<td align="center">512</td>
</tr>
<tr>
<td align="center">3c</td>
<td align="center">256</td>
<td align="center">128</td>
<td align="center">-</td>
<td align="center">-</td>
<td align="center">128</td>
<td align="center">-</td>
<td align="center">1024</td>
<td align="center">256</td>
<td align="center">-</td>
<td align="center">256</td>
</tr>
<tr>
<td align="center">3d</td>
<td align="center">128</td>
<td align="center">64</td>
<td align="center">-</td>
<td align="center">-</td>
<td align="center">64</td>
<td align="center">-</td>
<td align="center">512</td>
<td align="center">256</td>
<td align="center">32</td>
<td align="center">32</td>
</tr>
<tr>
<td align="center">5</td>
<td align="center">64</td>
<td align="center">64</td>
<td align="center">-</td>
<td align="center">64</td>
<td align="center">16</td>
<td align="center">512</td>
<td align="center">128</td>
<td align="center">64</td>
<td align="center">256</td>
<td align="center">128</td>
</tr>
<tr>
<td align="center">6a</td>
<td align="center">32</td>
<td align="center">16</td>
<td align="center">-</td>
<td align="center">32</td>
<td align="center">4</td>
<td align="center">128</td>
<td align="center">64</td>
<td align="center">32</td>
<td align="center">128</td>
<td align="center">64</td>
</tr>
<tr>
<td align="center">6b</td>
<td align="center">32</td>
<td align="center">8</td>
<td align="center">-</td>
<td align="center">16</td>
<td align="center">4</td>
<td align="center">128</td>
<td align="center">32</td>
<td align="center">32</td>
<td align="center">128</td>
<td align="center">32</td>
</tr>
<tr>
<td align="center">6c</td>
<td align="center">16</td>
<td align="center">8</td>
<td align="center">-</td>
<td align="center">4</td>
<td align="center">2</td>
<td align="center">64</td>
<td align="center">32</td>
<td align="center">16</td>
<td align="center">64</td>
<td align="center">32</td>
</tr>
<tr>
<td align="center">Drug 1</td>
<td align="center">2</td>
<td align="center">4</td>
<td align="center">2</td>
<td align="center">2</td>
<td align="center">1</td>
<td align="center">32</td>
<td align="center">8</td>
<td align="center">8</td>
<td align="center">32</td>
<td align="center">64</td>
</tr>
<tr>
<td align="center">Drug 2</td>
<td align="center">-</td>
<td align="center">32</td>
<td align="center">-</td>
<td align="center">8</td>
<td align="center">2</td>
<td align="center">-</td>
<td align="center">16</td>
<td align="center">8</td>
<td align="center">-</td>
<td align="center">-</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="T5" position="float">
<label>TABLE 5</label>
<caption>
<p>MBC (&#x3bc;g/mL) value for bacterial strains and MFC (&#x3bc;g/mL) value for fungi strains results in investigating the antimicrobial properties of the synthesized derivatives.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th rowspan="2" align="center">Compound</th>
<th colspan="4" align="center">Gram-positive pathogenic bacterial</th>
<th colspan="4" align="center">Gram-negative pathogenic bacterial</th>
<th colspan="2" align="center">Fungi strain</th>
</tr>
<tr>
<th align="center">ATCC 11778 <italic>Bacillus cereus</italic>
</th>
<th align="center">ATCC 15352 <italic>Streptococcus equinus</italic>
</th>
<th align="center">ATCC 25729 <italic>Rhodococcus equi</italic>
</th>
<th align="center">ATCC 29213 <italic>Staphylococcus aureus</italic>
</th>
<th align="center">ATCC 7002 <italic>Proteus mirabilis</italic>
</th>
<th align="center">ATCC 19606 <italic>Acinetobacter baumannii</italic>
</th>
<th align="center">ATCC 9610 <italic>Yersinia enterocolitica</italic>
</th>
<th align="center">ATCC 25922 <italic>Escherichia coli</italic>
</th>
<th align="center">ATCC 10231 <italic>Candida albicans</italic>
</th>
<th align="center">ATCC 1022 <italic>Aspergillus fumigatus Fresenius</italic>
</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="center">3a</td>
<td align="center">1024</td>
<td align="center">1024</td>
<td align="center">-</td>
<td align="center">-</td>
<td align="center">2048</td>
<td align="center">-</td>
<td align="center">2048</td>
<td align="center">2048</td>
<td align="center">-</td>
<td align="center">2048</td>
</tr>
<tr>
<td align="center">3b</td>
<td align="center">512</td>
<td align="center">512</td>
<td align="center">-</td>
<td align="center">-</td>
<td align="center">1024</td>
<td align="center">-</td>
<td align="center">2048</td>
<td align="center">1024</td>
<td align="center">-</td>
<td align="center">1024</td>
</tr>
<tr>
<td align="center">3c</td>
<td align="center">256</td>
<td align="center">256</td>
<td align="center">-</td>
<td align="center">-</td>
<td align="center">256</td>
<td align="center">-</td>
<td align="center">1024</td>
<td align="center">512</td>
<td align="center">-</td>
<td align="center">512</td>
</tr>
<tr>
<td align="center">3d</td>
<td align="center">256</td>
<td align="center">128</td>
<td align="center">-</td>
<td align="center">-</td>
<td align="center">256</td>
<td align="center">-</td>
<td align="center">1024</td>
<td align="center">512</td>
<td align="center">64</td>
<td align="center">64</td>
</tr>
<tr>
<td align="center">5</td>
<td align="center">128</td>
<td align="center">64</td>
<td align="left">-</td>
<td align="center">256</td>
<td align="center">64</td>
<td align="center">512</td>
<td align="center">254</td>
<td align="center">128</td>
<td align="center">512</td>
<td align="center">256</td>
</tr>
<tr>
<td align="center">6a</td>
<td align="center">64</td>
<td align="center">32</td>
<td align="center">-</td>
<td align="center">64</td>
<td align="center">16</td>
<td align="center">512</td>
<td align="center">128</td>
<td align="center">128</td>
<td align="center">512</td>
<td align="center">128</td>
</tr>
<tr>
<td align="center">6b</td>
<td align="center">32</td>
<td align="center">16</td>
<td align="center">-</td>
<td align="center">32</td>
<td align="center">8</td>
<td align="center">256</td>
<td align="center">64</td>
<td align="center">64</td>
<td align="center">256</td>
<td align="center">128</td>
</tr>
<tr>
<td align="center">6c</td>
<td align="center">32</td>
<td align="center">16</td>
<td align="center">-</td>
<td align="center">8</td>
<td align="center">4</td>
<td align="center">128</td>
<td align="center">32</td>
<td align="center">32</td>
<td align="center">128</td>
<td align="center">64</td>
</tr>
<tr>
<td align="center">Drug 1</td>
<td align="center">4</td>
<td align="center">8</td>
<td align="center">4</td>
<td align="center">4</td>
<td align="center">2</td>
<td align="center">64</td>
<td align="center">8</td>
<td align="center">16</td>
<td align="center">64</td>
<td align="center">128</td>
</tr>
<tr>
<td align="center">Drug 2</td>
<td align="center">-</td>
<td align="center">64</td>
<td align="center">-</td>
<td align="center">16</td>
<td align="center">4</td>
<td align="center">-</td>
<td align="center">32</td>
<td align="center">32</td>
<td align="center">-</td>
<td align="center">-</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="T6" position="float">
<label>TABLE 6</label>
<caption>
<p>IZD (mm) value results in investigating the antimicrobial properties of the synthesized derivatives.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th rowspan="2" align="center">Compound</th>
<th colspan="4" align="center">Gram-positive pathogenic bacterial</th>
<th colspan="4" align="center">Gram-negative pathogenic bacterial</th>
<th colspan="2" align="center">Fungi strain</th>
</tr>
<tr>
<th align="center">ATCC 11778 <italic>Bacillus cereus</italic>
</th>
<th align="center">ATCC 15352 <italic>Streptococcus equinus</italic>
</th>
<th align="center">ATCC 25729 <italic>Rhodococcus equi</italic>
</th>
<th align="center">ATCC 29213 <italic>Staphylococcus aureus</italic>
</th>
<th align="center">ATCC 7002 <italic>Proteus mirabilis</italic>
</th>
<th align="center">ATCC 19606 <italic>Acinetobacter baumannii</italic>
</th>
<th align="center">ATCC 9610 <italic>Yersinia enterocolitica</italic>
</th>
<th align="center">ATCC 25922 <italic>Escherichia coli</italic>
</th>
<th align="center">ATCC 10231 <italic>Candida albicans</italic>
</th>
<th align="center">ATCC 1022 <italic>Aspergillus fumigatus Fresenius</italic>
</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="center">3a</td>
<td align="center">14.29</td>
<td align="center">14.53</td>
<td align="center">-</td>
<td align="center">-</td>
<td align="center">17.38</td>
<td align="center">-</td>
<td align="center">15.37</td>
<td align="center">13.02</td>
<td align="center">-</td>
<td align="center">15.19</td>
</tr>
<tr>
<td align="center">3b</td>
<td align="center">14.01</td>
<td align="center">14.45</td>
<td align="left">-</td>
<td align="center">-</td>
<td align="center">17.50</td>
<td align="center">-</td>
<td align="center">15.16</td>
<td align="center">12.86</td>
<td align="center">-</td>
<td align="center">18.73</td>
</tr>
<tr>
<td align="center">3c</td>
<td align="center">14.57</td>
<td align="center">14.76</td>
<td align="center">-</td>
<td align="center">-</td>
<td align="center">18.67</td>
<td align="center">-</td>
<td align="center">14.81</td>
<td align="center">13.52</td>
<td align="center">-</td>
<td align="center">17.91</td>
</tr>
<tr>
<td align="center">3d</td>
<td align="center">14.35</td>
<td align="center">14.38</td>
<td align="center">-</td>
<td align="center">-</td>
<td align="center">18.94</td>
<td align="center">-</td>
<td align="center">15.37</td>
<td align="center">13.44</td>
<td align="center">25.12</td>
<td align="center">27.53</td>
</tr>
<tr>
<td align="center">5</td>
<td align="center">14.58</td>
<td align="center">16.12</td>
<td align="center">-</td>
<td align="center">16.94</td>
<td align="center">20.89</td>
<td align="center">11.99</td>
<td align="center">17.08</td>
<td align="center">16.41</td>
<td align="center">18.23</td>
<td align="center">19.56</td>
</tr>
<tr>
<td align="center">6a</td>
<td align="center">17.76</td>
<td align="center">15.99</td>
<td align="center">-</td>
<td align="center">19.43</td>
<td align="center">21.02</td>
<td align="center">12.64</td>
<td align="center">17.96</td>
<td align="center">17.73</td>
<td align="center">20.12</td>
<td align="center">23.17</td>
</tr>
<tr>
<td align="center">6b</td>
<td align="center">17.29</td>
<td align="center">17.68</td>
<td align="center">-</td>
<td align="center">19.83</td>
<td align="center">20.84</td>
<td align="center">13.16</td>
<td align="center">17.92</td>
<td align="center">17.35</td>
<td align="center">19.46</td>
<td align="center">25.32</td>
</tr>
<tr>
<td align="center">6c</td>
<td align="center">18.19</td>
<td align="center">17.31</td>
<td align="center">-</td>
<td align="center">20.03</td>
<td align="center">21.99</td>
<td align="center">12.50</td>
<td align="center">18.15</td>
<td align="center">17.38</td>
<td align="center">20.75</td>
<td align="center">24.01</td>
</tr>
<tr>
<td align="center">Drug 1</td>
<td align="center">20.21</td>
<td align="center">16.85</td>
<td align="center">22.43</td>
<td align="center">19.38</td>
<td align="center">23.67</td>
<td align="center">15.29</td>
<td align="center">18.72</td>
<td align="center">16.41</td>
<td align="center">23.48</td>
<td align="center">21.40</td>
</tr>
<tr>
<td align="center">Drug 2</td>
<td align="center">-</td>
<td align="center">15.96</td>
<td align="center">-</td>
<td align="center">19.61</td>
<td align="center">20.48</td>
<td align="center">-</td>
<td align="center">17.81</td>
<td align="center">17.37</td>
<td align="center">-</td>
<td align="center">-</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Gentamicin, Cefazolin, Terbinafine, and Tolnaftate are known antibiotics, and, in this study, they were used to compare the antibacterial properties of the synthetic compounds. Gentamicin (antibacterial activity Tables, drug 1) and Cefazolin (antibacterial activity Tables, drug 2) are recognized potent antibacterial drugs, while Terbinafine (antifungal activity Tables, drug 1) and Tolnaftate (antifungal activity Tables, drug 2) are recognized potent antifungal drugs.</p>
<p>In terms of antimicrobial activity, the highest effectiveness was observed for 6c. The order of antimicrobial activity is described as 6b &#x3e; 6a&#x3e;5&#x3e;3d&#x3e; 3c &#x3e; 3b &#x3e; 3a. From the comparison of the structures, it can be concluded that the effectiveness of the compounds against bacterial species depends first on the hydroxyl and ester groups of the compounds, then on having an electron-rich benzene ring, and finally on substitutions with more methyl. The review of the literature showed that compounds containing oxygen and esters have high antibacterial properties (<xref ref-type="bibr" rid="B26">Shafiee et al., 1973</xref>; <xref ref-type="bibr" rid="B7">Dongamanti et al., 2015</xref>; <xref ref-type="bibr" rid="B36">Xie et al., 2015</xref>; <xref ref-type="bibr" rid="B23">Qin et al., 2020</xref>; <xref ref-type="bibr" rid="B29">Shi et al., 2021</xref>); here, it was also determined that the esterification of ciprofloxacin by glycerol led to the synthesis of compounds with significant antimicrobial properties.</p>
<p>In terms of antifungal activity, the highest effectiveness was observed for 3d. The MIC values for this combination were 32&#xa0;&#x3bc;g/mL for both <italic>Candida albicans</italic> and <italic>Aspergillus fumigatus Fresenius</italic>. The presence of sulfur and the electron-rich benzene ring in the structure of this compound is the reason for the effectiveness of this compound in terms of antifungal activity. The order of antifungal activity is described as 6c &#x3e; 6b &#x3e; 6a&#x3e;5&#x3e;3c &#x3e; 3b &#x3e; 3a. By examining the structures of the derivatives, the order of effectiveness can be attributed to compounds with hydroxyl and ester groups, followed by the benzene ring, and, finally, substitutions with more methyl, just like the case for the antibacterial activity. Therefore, it was proved here that the presence of sulfur in the structure of 3d (methylthio) plays a significant role in antifungal activity (<xref ref-type="bibr" rid="B21">Pathania et al., 2019</xref>; <xref ref-type="bibr" rid="B13">Hua et al., 2020</xref>; <xref ref-type="bibr" rid="B2">Asif and Imran, 2022</xref>).</p>
<p>Comparing the results with known drugs such as Gentamicin, Cefazolin, Terbinafine, and Tolnaftate proved that the synthesized compounds are more active than them. For example, Cefazolin was ineffective against <italic>Bacillus cereus</italic> and <italic>Acinetobacter baumannii</italic>, but the MIC values for 6c were observed to be 16&#xa0;&#x3bc;g/mL and 64&#xa0;&#x3bc;g/mL, respectively. In terms of antifungal activity, Tolnaftate was not effective against <italic>Candida albicans</italic> and <italic>Aspergillus fumigatus Fresenius</italic>, but an MIC value of 32&#xa0;&#x3bc;g/mL was observed for 3d.</p>
<p>As a final result, 6c and 3d can be reported as effective agents with antimicrobial and antifungal activities, respectively (<xref ref-type="fig" rid="F10">Figure 10</xref>). After being proven to be safe and passing additional supplementary pharmacology tests, including <italic>in vivo</italic>, cytotoxicity, etc., they can be suggested as strong effective drugs.</p>
<fig id="F10" position="float">
<label>FIGURE 10</label>
<caption>
<p>The most effective synthesized structures in terms of antibacterial activity (6c) and antifungal activity (3d).</p>
</caption>
<graphic xlink:href="fmats-10-1255955-g010.tif"/>
</fig>
</sec>
</sec>
<sec sec-type="conclusion" id="s4">
<title>4 Conclusion</title>
<p>In summary, in this research, ciprofloxacin was used as a starting material for synthesizing new amidification and esterification derivatives of ciprofloxacin. The synthetic compounds were confirmed by using proton nuclear magnetic resonance (<sup>1</sup>H NMR), carbon-13 nuclear magnetic resonance (<sup>13</sup>C NMR), mass spectrometry (MS), and elemental analysis (EA). IZD, MIC, MBC, and MFC were measured for antimicrobial properties, including Gram-positive antibacterial, Gram-negative antibacterial, and antifungal based on clinical and laboratory standards. In some derivatives, more effective antibacterial and antifungal properties were observed than for some commercial drugs. In continuation of the biological investigations, the <italic>in vitro</italic> anticancer activity of the derivatives against breast cancer cells was evaluated by the MTT method. In terms of anticancer properties, the effectiveness of some derivatives was similar to abemaciclib, a well-known anti-breast cancer drug. In biological evaluations, a clear relationship between the structure of the derivatives and biological properties such as antibacterial, antifungal, and anticancer was observed. As the results of biological activities have proven, some derivatives have higher antimicrobial and anticancer properties than commercial drugs used in the market. Therefore, the synthesized compounds in this study are important in this regard; it is suggested that other supplementary pharmacological and biological assays, such as <italic>in silico</italic> studies on the mechanism of action, <italic>in vivo</italic> tests, cytotoxicity tests, etc., be performed and if positive findings can be seen, then these compounds can be reported as effective leads for further preclinical and clinical studies.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="s5">
<title>Data availability statement</title>
<p>The original contributions presented in the study are available upon request, further inquiries can be directed to the corresponding author.</p>
</sec>
<sec id="s6">
<title>Author contributions</title>
<p>GA: Writing&#x2013;original draft. ZA-O: Conceptualization, Supervision, Writing&#x2013;original draft, Writing&#x2013;review and editing.</p>
</sec>
<sec id="s7">
<title>Funding</title>
<p>The authors declare that no financial support was received for the research, authorship, and/or publication of this article.</p>
</sec>
<sec sec-type="COI-statement" id="s8">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s9">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aldred</surname>
<given-names>K. J.</given-names>
</name>
<name>
<surname>Kerns</surname>
<given-names>R. J.</given-names>
</name>
<name>
<surname>Osheroff</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Mechanism of quinolone action and resistance</article-title>. <source>Biochemistry</source> <volume>53</volume> (<issue>10</issue>), <fpage>1565</fpage>&#x2013;<lpage>1574</lpage>. <pub-id pub-id-type="doi">10.1021/bi5000564</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Asif</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Imran</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Abida</surname>
</name>
</person-group> (<year>2022</year>). <article-title>Antimicrobial activities of various thiazine based heterocyclic compounds: A mini-review</article-title>. <source>Mini-Reviews Org. Chem.</source> <volume>19</volume> (<issue>2</issue>), <fpage>166</fpage>&#x2013;<lpage>172</lpage>. <pub-id pub-id-type="doi">10.2174/1570193x18666210629102447</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beyzaei</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Aryan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Moghaddam-Manesh</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ghasemi</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Karimi</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Delarami</surname>
<given-names>H. S.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Evaluation and structure-activity relationship analysis of a new series of 4-imino-5H-pyrazolo [3, 4-d] pyrimidin-5-amines as potential antibacterial agents</article-title>. <source>J. Mol. Struct.</source> <volume>1144</volume>, <fpage>273</fpage>&#x2013;<lpage>279</lpage>. <pub-id pub-id-type="doi">10.1016/j.molstruc.2017.05.050</pub-id>
</citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bolakatti</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Palkar</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Katagi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hampannavar</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Karpoormath</surname>
<given-names>R. V.</given-names>
</name>
<name>
<surname>Ninganagouda</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Novel series of benzo [d] thiazolyl substituted-2-quinolone hybrids: design, synthesis, biological evaluation and <italic>in-silico</italic> insights</article-title>. <source>J. Mol. Struct.</source> <volume>1227</volume>, <fpage>129413</fpage>. <pub-id pub-id-type="doi">10.1016/j.molstruc.2020.129413</pub-id>
</citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Das</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Verma</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Ghosh</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ramamurthy</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Antibiotic resistance in <italic>Vibrio cholerae</italic>: understanding the ecology of resistance genes and mechanisms</article-title>. <source>Vaccine</source> <volume>38</volume>, <fpage>A83</fpage>&#x2013;<lpage>A92</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2019.06.031</pub-id>
</citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dib</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ouchetto</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ouchetto</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hafid</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Khouili</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Recent developments of quinoline derivatives and their potential biological activities</article-title>. <source>Curr. Org. Synth.</source> <volume>18</volume> (<issue>3</issue>), <fpage>248</fpage>&#x2013;<lpage>269</lpage>. <pub-id pub-id-type="doi">10.2174/1570179417666201216162055</pub-id>
</citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dongamanti</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Aamate</surname>
<given-names>V. K.</given-names>
</name>
<name>
<surname>Devulapally</surname>
<given-names>M. G.</given-names>
</name>
<name>
<surname>Gundu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kotni</surname>
<given-names>M. K.</given-names>
</name>
<name>
<surname>Manga</surname>
<given-names>V.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Synthesis, antimicrobial activity and molecular docking of novel tetracyclic scaffolds incorporating a flavonoid framework with medium sized oxygen heterocycles</article-title>. <source>Bioorg. Med. Chem. Lett.</source> <volume>25</volume> (<issue>4</issue>), <fpage>898</fpage>&#x2013;<lpage>903</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmcl.2014.12.066</pub-id>
</citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>El-Shershaby</surname>
<given-names>M. H.</given-names>
</name>
<name>
<surname>El-Gamal</surname>
<given-names>K. M.</given-names>
</name>
<name>
<surname>Bayoumi</surname>
<given-names>A. H.</given-names>
</name>
<name>
<surname>El-Adl</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Alswah</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ahmed</surname>
<given-names>H. E.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>The antimicrobial potential and pharmacokinetic profiles of novel quinoline-based scaffolds: synthesis and <italic>in silico</italic> mechanistic studies as dual dna gyrase and dhfr inhibitors</article-title>. <source>New J. Chem.</source> <volume>45</volume> (<issue>31</issue>), <fpage>13986</fpage>&#x2013;<lpage>14004</lpage>. <pub-id pub-id-type="doi">10.1039/d1nj02838c</pub-id>
</citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Etemadi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shiri</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Eshghi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Akbarzadeh</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Saadat</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Mozafari</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Synthesis, characterisation, and <italic>in vitro</italic> antibacterial evaluation of a new class of 2-substituted-4-methyl-7, 8-dihydro-5H-pyrimido [4, 5-d] thiazolo [3, 2-a] pyrimidines</article-title>. <source>J. Chem. Res.</source> <volume>40</volume> (<issue>10</issue>), <fpage>600</fpage>&#x2013;<lpage>603</lpage>. <pub-id pub-id-type="doi">10.3184/174751916x14737838285904</pub-id>
</citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferreira</surname>
<given-names>S. B.</given-names>
</name>
<name>
<surname>Kaiser</surname>
<given-names>C. R.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Pyrazine derivatives: A patent review (2008&#x2013;present)</article-title>. <source>Expert Opin. Ther. Pat.</source> <volume>22</volume> (<issue>9</issue>), <fpage>1033</fpage>&#x2013;<lpage>1051</lpage>. <pub-id pub-id-type="doi">10.1517/13543776.2012.714370</pub-id>
</citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Foti</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Devadoss</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Winkler</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Collins</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>G. C.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Oxidation of the guanine nucleotide pool underlies cell death by bactericidal antibiotics</article-title>. <source>Science</source> <volume>336</volume> (<issue>6079</issue>), <fpage>315</fpage>&#x2013;<lpage>319</lpage>. <pub-id pub-id-type="doi">10.1126/science.1219192</pub-id>
</citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Quinolone hybrids and their anti-cancer activities: an overview</article-title>. <source>Eur. J. Med. Chem.</source> <volume>165</volume>, <fpage>59</fpage>&#x2013;<lpage>79</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejmech.2019.01.017</pub-id>
</citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hooper</surname>
<given-names>D. C.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Emerging mechanisms of fluoroquinolone resistance</article-title>. <source>Emerg. Infect. Dis.</source> <volume>7</volume> (<issue>2</issue>), <fpage>337</fpage>&#x2013;<lpage>341</lpage>. <pub-id pub-id-type="doi">10.3201/eid0702.010239</pub-id>
</citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hua</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>N.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Studies on the novel pyridine sulfide containing SDH based heterocyclic amide fungicide</article-title>. <source>Pest Manag. Sci.</source> <volume>76</volume> (<issue>7</issue>), <fpage>2368</fpage>&#x2013;<lpage>2378</lpage>. <pub-id pub-id-type="doi">10.1002/ps.5773</pub-id>
</citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huigens</surname>
<given-names>R. W.</given-names>
<suffix>III</suffix>
</name>
<name>
<surname>Brummel</surname>
<given-names>B. R.</given-names>
</name>
<name>
<surname>Tenneti</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Garrison</surname>
<given-names>A. T.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Pyrazine and phenazine heterocycles: platforms for total synthesis and drug discovery</article-title>. <source>Molecules</source> <volume>27</volume> (<issue>3</issue>), <fpage>1112</fpage>. <pub-id pub-id-type="doi">10.3390/molecules27031112</pub-id>
</citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jamshidi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Naimi&#x2010;Jamal</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Safavi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>RayatSanati</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Azerang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Tahghighi</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Synthesis and biological activity profile of novel triazole/quinoline hybrids</article-title>. <source>Chem. Biol. Drug Des.</source> <volume>100</volume> (<issue>6</issue>), <fpage>935</fpage>&#x2013;<lpage>946</lpage>. <pub-id pub-id-type="doi">10.1111/cbdd.14031</pub-id>
</citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kudiyarova</surname>
<given-names>A. D.</given-names>
</name>
<name>
<surname>Ashurov</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Ibragimov</surname>
<given-names>A. B.</given-names>
</name>
<name>
<surname>Sabirov</surname>
<given-names>V. K.</given-names>
</name>
<name>
<surname>Ibragimov</surname>
<given-names>B. T.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Synthesis, &#x441;rystal structure and Hirshfeld surface analysis of ciprofloxacinium tetrachlorocadmium dihydrate</article-title>. <source>Chem. Data Collect.</source> <volume>31</volume>, <fpage>100633</fpage>. <pub-id pub-id-type="doi">10.1016/j.cdc.2020.100633</pub-id>
</citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matada</surname>
<given-names>B. S.</given-names>
</name>
<name>
<surname>Pattanashettar</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Yernale</surname>
<given-names>N. G.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>A comprehensive review on the biological interest of quinoline and its derivatives</article-title>. <source>Bioorg. Med. Chem.</source> <volume>32</volume>, <fpage>115973</fpage>. <pub-id pub-id-type="doi">10.1016/j.bmc.2020.115973</pub-id>
</citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moghaddam-Manesh</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ghazanfari</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Sheikhhosseini</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Akhgar</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Synthesis, characterization and antimicrobial evaluation of novel 6&#x27;-Amino-spiro [indeno [1, 2-b] quinoxaline [1, 3] dithiine]-5&#x27;-carbonitrile derivatives</article-title>. <source>Acta Chim. Slov.</source> <volume>67</volume> (<issue>1</issue>), <fpage>276</fpage>&#x2013;<lpage>282</lpage>. <pub-id pub-id-type="doi">10.17344/acsi.2019.5437</pub-id>
</citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moghaddam&#x2010;manesh</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Beyzaei</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Heidari Majd</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hosseinzadegan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ghazvini</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Investigation and comparison of biological effects of regioselectively synthesized thiazole derivatives</article-title>. <source>J. Heterocycl. Chem.</source> <volume>58</volume> (<issue>7</issue>), <fpage>1525</fpage>&#x2013;<lpage>1530</lpage>. <pub-id pub-id-type="doi">10.1002/jhet.4278</pub-id>
</citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moghaddam&#x2010;Manesh</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hosseinzadegan</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Introducing new method for the synthesis of polycyclic compounds containing [1, 3] dithiine derivatives, with anticancer and antibacterial activities against common bacterial strains between aquatic and human</article-title>. <source>J. Heterocycl. Chem.</source> <volume>58</volume> (<issue>11</issue>), <fpage>2174</fpage>&#x2013;<lpage>2180</lpage>. <pub-id pub-id-type="doi">10.1002/jhet.4345</pub-id>
</citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pathania</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Narang</surname>
<given-names>R. K.</given-names>
</name>
<name>
<surname>Rawal</surname>
<given-names>R. K.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Role of sulphur-heterocycles in medicinal chemistry: an update</article-title>. <source>Eur. J. Med. Chem.</source> <volume>180</volume>, <fpage>486</fpage>&#x2013;<lpage>508</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejmech.2019.07.043</pub-id>
</citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pruchnik</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kral</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Poradowski</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Pawlak</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Drynda</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Obmi&#x144;ska-Mrukowicz</surname>
<given-names>B.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>New cytotoxic butyltin complexes with 2-sulfobenzoic acid: molecular interaction with lipid bilayers and dna as well as <italic>in vitro</italic> anticancer activity</article-title>. <source>Chemico-Biological Interact.</source> <volume>243</volume>, <fpage>107</fpage>&#x2013;<lpage>118</lpage>. <pub-id pub-id-type="doi">10.1016/j.cbi.2015.11.007</pub-id>
</citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qin</surname>
<given-names>H.-L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.-W.</given-names>
</name>
<name>
<surname>Ravindar</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Rakesh</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Antibacterial activities with the structure-activity relationship of coumarin derivatives</article-title>. <source>Eur. J. Med. Chem.</source> <volume>207</volume>, <fpage>112832</fpage>. <pub-id pub-id-type="doi">10.1016/j.ejmech.2020.112832</pub-id>
</citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Shang</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>A new approach to replace antibiotics with natural pigment derivatives: surface modification on the titanium implants</article-title>. <source>Appl. Surf. Sci.</source> <volume>608</volume>, <fpage>155122</fpage>. <pub-id pub-id-type="doi">10.1016/j.apsusc.2022.155122</pub-id>
</citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schneider</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Merbouh</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Keerthisinghe</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Antonietti</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Filonenko</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Microwave-irradiated rapid synthesis of antimicrobial pyrazine derivatives in reactive eutectic media</article-title>. <source>Green Chem.</source> <volume>24</volume> (<issue>24</issue>), <fpage>9745</fpage>&#x2013;<lpage>9754</lpage>. <pub-id pub-id-type="doi">10.1039/d2gc03122a</pub-id>
</citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shafiee</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lalezari</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Yazdany</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Pournorouz</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>1973</year>). <article-title>Selenium heterocycles VIH: synthesis and antibacterial activity of selenosemicarbazide and 1,3,4-selenadiazolylcarbamic acid esters</article-title>. <source>J. Pharm. Sci.</source> <volume>62</volume> (<issue>5</issue>), <fpage>839</fpage>&#x2013;<lpage>840</lpage>. <pub-id pub-id-type="doi">10.1002/jps.2600620538</pub-id>
</citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharma</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Chowdhary</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Legac</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rosenthal</surname>
<given-names>P. J.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>V.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Quinoline&#x2010;based heterocyclic hydrazones: design, synthesis, anti&#x2010;plasmodial assessment, and mechanistic insights</article-title>. <source>Chem. Biol. Drug Des.</source> <volume>101</volume> (<issue>4</issue>), <fpage>829</fpage>&#x2013;<lpage>836</lpage>. <pub-id pub-id-type="doi">10.1111/cbdd.14185</pub-id>
</citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shashikant</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bains</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Chawla</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kaushik</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kandi</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>
<italic>In-vitro</italic> antimicrobial and anti-inflammatory activity of modified solvent evaporated ethanolic extract of calocybe indica: GCMS and HPLC characterization</article-title>. <source>Int. J. Food Microbiol.</source> <volume>376</volume>, <fpage>109741</fpage>. <pub-id pub-id-type="doi">10.1016/j.ijfoodmicro.2022.109741</pub-id>
</citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname>
<given-names>Y.-g.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>R.-r.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>C.-m.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>X.-r.</given-names>
</name>
<name>
<surname>Ettelaie</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>On the mechanism behind enhanced antibacterial activity of alkyl gallate esters against foodborne pathogens and its application in Chinese icefish preservation</article-title>. <source>Food Microbiol.</source> <volume>99</volume>, <fpage>103817</fpage>. <pub-id pub-id-type="doi">10.1016/j.fm.2021.103817</pub-id>
</citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tambat</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Mulani</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ahmad</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Shaikh</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ahmed</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Pyrazine derivatives&#x2014;versatile scaffold</article-title>. <source>Russ. J. Bioorg. Chem.</source> <volume>48</volume> (<issue>5</issue>), <fpage>865</fpage>&#x2013;<lpage>895</lpage>. <pub-id pub-id-type="doi">10.1134/s1068162022050259</pub-id>
</citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tantawy</surname>
<given-names>E. S.</given-names>
</name>
<name>
<surname>Amer</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Mohamed</surname>
<given-names>E. K.</given-names>
</name>
<name>
<surname>Abd Alla</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Nafie</surname>
<given-names>M. S.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Synthesis, characterization of some pyrazine derivatives as anti-cancer agents: <italic>in vitro</italic> and <italic>in silico</italic> approaches</article-title>. <source>J. Mol. Struct.</source> <volume>1210</volume>, <fpage>128013</fpage>. <pub-id pub-id-type="doi">10.1016/j.molstruc.2020.128013</pub-id>
</citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Terreni</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Taccani</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pregnolato</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>New antibiotics for multidrug-resistant bacterial strains: latest research developments and future perspectives</article-title>. <source>Molecules</source> <volume>26</volume> (<issue>9</issue>), <fpage>2671</fpage>. <pub-id pub-id-type="doi">10.3390/molecules26092671</pub-id>
</citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uncu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Donici</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Valica</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Vislouh</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Gonciar</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Parii</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Development and validation of an assay method for ciprofloxacin hydrochloride determination in combination ear drops</article-title>. <source>Chem. J. Moldova</source> <volume>14</volume> (<issue>2</issue>), <fpage>56</fpage>&#x2013;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.19261/cjm.2019.607</pub-id>
</citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Tao</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Zhan</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Anticancer activity of polysaccharides produced from glycerol and crude glycerol by an endophytic fungus Chaetomium globosum CGMCC 6882 on human lung cancer A549 cells</article-title>. <source>Biomolecules</source> <volume>8</volume> (<issue>4</issue>), <fpage>171</fpage>. <pub-id pub-id-type="doi">10.3390/biom8040171</pub-id>
</citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Determination of antibiotic residues in aquaculture products by liquid chromatography tandem mass spectrometry: recent trends and developments from 2010 to 2020</article-title>. <source>Separations</source> <volume>9</volume> (<issue>2</issue>), <fpage>35</fpage>. <pub-id pub-id-type="doi">10.3390/separations9020035</pub-id>
</citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xie</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Antibacterial activities of flavonoids: structure-activity relationship and mechanism</article-title>. <source>Curr. Med. Chem.</source> <volume>22</volume> (<issue>1</issue>), <fpage>132</fpage>&#x2013;<lpage>149</lpage>. <pub-id pub-id-type="doi">10.2174/0929867321666140916113443</pub-id>
</citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhanel</surname>
<given-names>G. G.</given-names>
</name>
<name>
<surname>Fontaine</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Adam</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Schurek</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Mayer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Noreddin</surname>
<given-names>A. M.</given-names>
</name>
<etal/>
</person-group> (<year>2006</year>). <article-title>A review of new fluoroquinolones: focus on their use in respiratory tract infections</article-title>. <source>Treat. Respir. Med.</source> <volume>5</volume>, <fpage>437</fpage>&#x2013;<lpage>465</lpage>. <pub-id pub-id-type="doi">10.2165/00151829-200605060-00009</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>